Business
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
Seasoned sales veteran from Medtronic tasked to build and lead U.S. commercialization infrastructure as CytoSorbents sells CytoSorb under U.S. FDA Emergency
About this update from Cytosorbents Corporation
[{"type":"text","content":"Seasoned sales veteran from Medtronic tasked to build and lead U.S. commercialization infrastructure as CytoSorbents sells CytoSorb under U.S. FDA Emergency Use Authorization for COVID-19 and leverages FDA Breakthrough Designation for potential future U.S. approval\n\n\nMONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of James Komsa as Vice President - U.S. Sales and Marketing.\n\n \n \n \n \n \n \n\n \nJames Komsa, seasoned sales executive from Medtronic, joins CytoSorbents as Vice President - U.S. Sales and Marketing.Over a distinguished 18 year career at Medtronic, Mr. Komsa was most recently Vice President of the Restorative Therapy Group (RTG) and the U.S. Pain Organization, with annual sales of $400 million and $1.1 billion, respectively, at the time. There, he was responsible for 16 business units, including Medtronic Spine, Neurology, ENT, Pain and others. Prior to that, Jim led the successful turnaround of Kyphon as U.S. Vice President Medtronic Spine Division. Formerly as Vice President, Northeast Region, Medtronic Cardiac and Vascular Group (CVG), Mr. Komsa was responsible for sales, marketing and operations for the Coronary, Structural Heart, Endovascular, and Cardiac Rhythm Disease Management business units, encompassing more than 300 full-time employees and generating more than $310 million in annual sales. \nPrior to his career at Medtronic, Mr. Komsa was Vice President at Hambrecht & Quist, where he helped lead the operations and rapid sales growth of two start-up companies, Paceart and Zymed, which were ultimately acquired by Medtronic and Philips, respectively. Most recently, Mr. Komsa was Executive Vice President and General Manager of privately-held Pathy Medical, a medical device company focused on improving surgical illumination.\nMr. James Komsa stated, \"I am excited to join the talented CytoSorbents team and look forward to leading and building a world-class sales and marketing infrastructure for U.S. commercialization during this major growth period for the company overall. In the U.S., we will continue to build the CytoSorb brand, al...